[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3964 Introduced in House (IH)]

<DOC>






115th CONGRESS
  1st Session
                                H. R. 3964

    To amend the Controlled Substances Act to establish additional 
  registration requirements for prescribers of opioids, and for other 
                               purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            October 5, 2017

  Mr. Roe of Tennessee (for himself, Ms. Kuster of New Hampshire, Mr. 
  MacArthur, Mrs. Radewagen, and Miss Gonzalez-Colon of Puerto Rico) 
 introduced the following bill; which was referred to the Committee on 
Energy and Commerce, and in addition to the Committee on the Judiciary, 
for a period to be subsequently determined by the Speaker, in each case 
for consideration of such provisions as fall within the jurisdiction of 
                        the committee concerned

_______________________________________________________________________

                                 A BILL


 
    To amend the Controlled Substances Act to establish additional 
  registration requirements for prescribers of opioids, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Opioid Addiction Prevention Act of 
2017''.

SEC. 2. REGISTRATION REQUIREMENTS FOR PRESCRIBERS.

    Section 303 of the Controlled Substances Act (21 U.S.C. 823) is 
amended by adding at the end the following:
    ``(k)(1) The Attorney General shall not register, or renew the 
registration of, a practitioner under subsection (f) who is licensed 
under State law to prescribe controlled substances in schedule II, III, 
or IV, unless the practitioner submits to the Attorney General, for 
each such registration or renewal request, a certification that the 
practitioner, during the applicable registration period, will not 
prescribe, for the initial treatment of acute pain, any schedule II, 
III, or IV opioid, other than an opioid prescription described in 
paragraph (3)--
            ``(A) without firstly or concomitantly prescribing one or 
        more non-opioid analgesics, if there are no contraindications 
        to such analgesics;
            ``(B) without clearly stating on the prescription the 
        diagnosis for which the opioid is prescribed;
            ``(C) unless the prescribed opioid dose is the lowest 
        effective dose;
            ``(D) an extended release or long acting formulation of the 
        opioid; and
            ``(E) in an amount in excess of the lesser of--
                    ``(i) a 10-day supply (for which no refill is 
                available); or
                    ``(ii) an opioid prescription limit established 
                under State law.
    ``(2) In this subsection, the term `acute pain'--
            ``(A) means pain with abrupt onset and caused by a discrete 
        injury, surgical procedure, or other illness of limited 
        duration; and
            ``(B) does not include--
                    ``(i) chronic pain;
                    ``(ii) pain being treated as part of cancer care;
                    ``(iii) hospice or other end-of-life care; or
                    ``(iv) pain being treated as part of palliative 
                care.
    ``(3) An opioid prescription described in this paragraph is a 
prescription--
            ``(A) for a schedule II, III, or IV opioid drug approved by 
        the Food and Drug Administration for an indication for the 
        treatment of addiction; and
            ``(B) that is for the treatment of addiction.''.
                                 <all>